Schering AG Enters Radiopharmaceuticals Market Via $128 Mil. Diatide Deal
Executive Summary
Schering AG hopes to accelerate its expansion into the radiopharmaceuticals market through a $128 mil. cash tender offer to acquire Diatide.
You may also be interested in...
Schering AG U.S. Expansion Plans Call For Sales Of $1.6 Bil. In 2005
Schering AG expects its U.S. business to approach $1.6 bil. in revenues by 2005, more than double its projected 1999 level of $750 mil.
Schering AG U.S. Expansion Plans Call For Sales Of $1.6 Bil. In 2005
Schering AG expects its U.S. business to approach $1.6 bil. in revenues by 2005, more than double its projected 1999 level of $750 mil.
Nycomed/Diatide Will Promote NeoTect As Less Invasive Than Lung Biopsy
Nycomed Amersham and marketing partner Diatide will promote NeoTect as a less invasive means of distinguishing malignant from benign lung mass compared to needle biopsy and lung surgery, which are more painful and produce higher rates of complications compared to NeoTect, the companies said.